Previous Meetings

GBCC 2015

Global Breast Cancer Conference 2015

07:30-08:10
Breakfast Symposium 1 (Sponsored by Sanofi-Aventis)
Venue: Halla Hall
  • Adjuvant Non-Anthracycline Regimen in Operable Breast Cancer - Changing the Standard of Care
    Yeesoo Chae (Department of Oncology, Kyungpook National Univ. Medical Center, Korea)
08:30-09:30
Plenary Lecture 3
Venue: Halla Hall
  • Precision Medicine - Implications for Breast Cancer Clinical Trial Design
    Jo Anne Zujewski (Clinical Investigations Branch, Cancer Therapy Evaluation Program, NIH Clinical Center, U.S.A.)
09:40-10:50
Symposium 3
TNBC (Triple Negative Breast Cancer)
Venue: Halla Hall
  • Current Management of TNBC
    Joohyuk Sohn (Department of Internal Medicine, Yonsei Univ. Medical Center, Korea)
  • Heterogeneity of TNBC
    Rebecca Dent (Division of Medical Oncology, National Cancer Centre Singapore, Singapore)
  • Subtype-directed Therapy of TNBC
    Ruth M. O’Regan (Division of Hematology/Oncology, Univ. of Wisconsin, U.S.A.)
Symposium 4
Targeted Therapy in Breast Cancer
Venue: Lotus Hall
  • PD1/PDL1 Targeted Immunotherapy in Breast Cancer
    David Page (Department of Medicine, Memorial Sloan-Kettering Cancer Center, U.S.A.)
  • PI3K/AKT/mTOR Pathway Inhibitors in Breast Cancer
    Yoon Sim Yap (Department of Medical Oncology, National Cancer Centre Singapore, Singapore)
  • CDK 4/6 Inhibitors
    Sudeep Gupta (Department of Medical Oncology, Tata Memorial Centre/Hospital, India)
11:00-12:10
Symposium 5
Hormone Positive Breast Cancer
Venue: Halla Hall
  • Adjuvant Endocrine Therapy in Premenopausal Women
    Seigo Nakamura (Department of Surgery, Division of Breast Surgical Oncology, Showa Univ., Japan)
  • Adjuvant Endocrine Therapy in Premenopausal Women in 2015
    Woo Chul Noh (Department of Surgery, Korea Cancer Center Hospital, Korea)
  • Luminal B Breast Cancer
    Giuseppe Viale (Department of Pathology, IEO Istituto Europeo di Oncologia, Italy)
Symposium 6
Companion Diagnostics
Venue: Lotus Hall
  • Ki-67 Labeling Index in Breast Cancer
    Gyungyub Gong (Department of Pathology, ASAN Medical Center, Korea)
  • ER, PR and HER2 Testing in Breast Cancer
    Young Kyung Bae (Department of Pathology, Yeungnam Univ. Medical Center, Korea)
  • NGS-based Diagnostics
    Woong-Yang Park (Samsung Genome Institute, Samsung Medical Center, Korea)
12:10-13:10
Luncheon Symposium 2 (Sponsored by Roche)
Venue: Halla Hall
  • Current and Future Perspectives in Treatment of Metastatic TNBC
    Yeon Hee Park (Department of Hematology-oncology, Samsung Medical Center, Korea)
13:20-14:30
ABRCA
Venue: Lotus Hall
  • Cancer Genetic Risk Assessment in Breast Cancer
    Soo Hwang Teo (Breast Cancer Research Group / Faculty of Medicine, Cancer Research Initiatives Foundation, Malaysia)
  • Clinical Significance of Variants of Unknown Significance (VUS) in BRCA1/2 Genes
    Ava Kwong (Department of Surgery, Queen Mary Hospital, Hong Kong)
  • Risk-reduction Surgery in BRCA Mutation Carriers
    Sung-Won Kim (The Breast & Endocrine Service, Department of Surgery, Daerim St. Mary’s Hospital, Korea)
  • Genetic Counseling in Asia
    Seigo Nakamura (Department of Surgery, Division of Breast Surgical Oncology, Showa Univ., Japan)
13:30-14:30
Plenary Lecture 4
Venue: Halla Hall
  • Steps towards Precision Treatment in Breast Cancer: Lessons from Safir01 Trial
    Fabrice Andre (Breast Cancer Unit, Institut Gustave Roussy, France)
14:40-15:50
Symposium 7
Hereditary Breast Cancer
Venue: Halla Hall
  • Management of BRCA1/2 Mutation Carriers
    Steven Narod (Familial Breast Cancer Research Unit, Women’s College Research Institute, Canada)
  • Characterising Cancer Risks for Carriers of Mutations in BRCA1, BRCA2, PALB2 and RAD51C Genes
    Antonis Antoniou (Public Health and Primary Care, Univ. of Cambridge, United Kingdom)
  • Absolute Risks and Hormonal/Lifestyle Risk Modifiers among BRCA Mutation Carriers, the IBCCS Experience
    Matti Rookus (Department of Epidemiology, Netherlands Cancer Institute, Netherlands)
Panel Discussion 3
Role of Trustuzumab in Small HER2+ Early Breast Cancer
Venue: Lotus Hall
  • Pros
    Seock-Ah Im (Department of Internal Medicine, Seoul National Univ. Hospital, Korea)
  • Cons
    Janice Tsang (Department of Clinical Oncology, Queen Mary Hospital, Hong Kong)
Oral Presentation 2
Venue: Weolla Room
  • [OP2-1] PSYCHOSOCIAL CHARACTERISTICS OF HONG KONG CHINESE FEMALES UNDERTAKING GENETIC COUNSELLING AND TESTING FOR HEREDITARY BREAST AND OVARIAN CANCERS
    Annie Tsz-Wai Chu (Department of Breast Surgery, The Univ. of Hong Kong, Hong Kong)
  • [OP2-2] EPITHELIAL-MESENCHYMAL TRANSITION INDUCED BY IL-6/STAT3 PATHWAY ACTIVATION IN RESIDUAL TUMOR PREDICT OUTCOME IN TRIPLE NEGATIVE BREAST CANCER PATIENTS AFTER NEOADJUVANT CHEMOTHERAPY
    Zhengkui Sun (Department of Breast Surgery, Jiangxi Cancer Hospital, China)
  • [OP2-3] COMMON GENETIC VARIANTS ASSOCIATED WITH BREAST CANCER AND A NEW MAMMOGRAPHIC DENSITY MEASURE, CIRROCUMULUS, THAT BETTER PREDICTS DISEASE
    Kevin Nguyen (Centre for Epidemiology & Biostatistics, Melbourne School of Population and Global Health, The Univ. of Melbourne, Australia) 
  • [OP2-4] COMPARING STRENGTHS OF BREAST CANCER RISK FACTORS MEASURED ON DIFFERENT SCALES USING ODDS PER ADJUSTED STANDARD DEVIATION (OPERA)
    John Hopper (Centre for Epidemiology & Biostatistics, Melbourne School of Population and Global Health, The Univ. of Melbourne, Australia)
  • [OP2-5] A PROPOSAL FOR A NEW CLASSIFICATION OF T4 BREAST CANCER AS STAGE IIIC: A REPORT FROM THE KOREAN BREAST CANCER SOCIETY
    Hee Jeong Kim (Department of Surgery, ASAN Medical Center, Korea)
  • [OP2-6] CONCURRENT GnRH AGONIST WITH CHEMOTHERAPY IMPROVE RESPONSE OF NEOADJUVANT CHEMOTHERAPY
    Taein Yoon (Division of Breast and Endocrine, Department of Surgery, ASAN Medical Center, Korea)
  • [OP2-7] THE IMPACT OF RAS/MAPK/S6K SIGNALING PATHWAY ON PREDICTION OF CLINICAL OUTCOME IN METASTATIC HER2 POSITIVE BREAST CANCER PATIENTS TREATED WITH TRASTUZUMAB
    Marek Svoboda (Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Czech Republic)
  • [OP2-8] FIBROBLAST GROWTH FACTOR RECEPTOR 4 EXPRESSION IS ASSOCIATED WITH RESISTANCE TO DOCETAXEL DURING NEOADJUVANT CHEMOTHERAPY IN TRIPLE NEGATIVE BREAST CANCER
    Jun Ho Lee (Division of Breast and Endocrine Surgery, Department of Surgery, Samsung Medical Center, Sungkyunkwan Univ. School of Medicine, Korea)
16:00-17:00
Panel Discussion 4
Oncoplastic Surgery for Small Breast
Venue: Halla Hall
  • Pros
    Barbara Lynn Smith (Division of Surgical Oncology, Massachusetts General Hospital, U.S.A.)
  • Cons
    Ava Kwong (Department of Surgery, Queen Mary Hospital, Hong Kong)
16:00-17:10
Education Session 2
Cancer Genomics
Venue: Weolla Room
  • Understanding of Genomics Technology
    Ju-Seog Lee (Systems Biology, MD Anderson Cancer Center, U.S.A.)
  • Overview of Breast Cancer Genomics
    Joon Jeong (Department of Surgery, Division of Breast and Endocrine Surgery, Gangnam Severance Hospital, Korea)
16:00-18:00
Nursing Session
Women's Health Care in Breast Cancer
Venue: Lotus Hall
  • Women’s Health Care in Breast Cancer
    So Young Park (Department of Internal Medicine, Cheil General Hospital, Korea)
  • Managing Menopausal Symptoms among Breast Cancer Survivors
    Hye Jin Joh (Seoul St. Mary’s Hospital, Korea)
  • Adopting Self-awareness after Breast Treatment
    Young Ran Yoon (Nursing Department of Woman Cancer Center, Ewha Womans Univ. Mokdong Hospital, Korea)
  • Pregnancy in Young Women with Breast Cancer
    Eunkyung Hwang (Breast Care Center, Seoul National Univ. Hospital, Korea)
  • The Role of Oncology Nurse in Sexual Management
    Eun-Young Jun (Nursing Department, Daejeon Univ., Korea)
17:00-18:00
Panel Discussion 5
Oncoplastic Surgery: Reconstruction Using Autologous Tissue vs. Artificial Implant
Venue: Halla Hall
  • Autologous Tissue
    Kyung Won Minn (Department of Plastic and Reconstructive Surgery, Seoul National Univ. Hospital, Korea)
  • Artificial Implant
    Yoshiko Iwahira (Breast Surgery Clinic, Japan)
18:00-19:00
Dinner Symposium (Sponsored by Kyowa Kirin)
Venue: Halla Hall
  • Clinical Impacts of Primary Prophylaxis for FN (Febrile Neutropenia) in Breast Cancer Patients
    Young Jin Suh (Breast Surgical Oncology/Surgery, St. Vincent’s Hospital, Korea)
Back to Previous Meetings